Edwards Lifesciences (NYSE:EW – Get Rating) had its price target trimmed by Truist Financial from $112.00 to $95.00 in a report published on Friday, Marketbeat Ratings reports. The brokerage currently has a buy rating on the medical research company’s stock. A number of other equities analysts have also recently commented on the company. Barclays assumed […]
Edwards Lifesciences (NYSE:EW – Get Rating) had its target price lowered by Cowen from $125.00 to $100.00 in a research report sent to investors on Friday morning, Stock Target Advisor reports. A number of other research analysts have also recently commented on the stock. Canaccord Genuity Group dropped their target price on shares of Edwards […]
BOSTON, Sept. 17, 2022 /PRNewswire/ Edwards Lifesciences Corporation announced results from CLASP IID, the first randomized controlled trial that directly compares two contemporary transcatheter. | September 17, 2022